Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 12, Issue 2, Pages 267-274Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.0c00647
Keywords
Farnesoid X receptor; NR1H4; bile acid receptor; nonalcoholic steatohepatitis; NASH
Categories
Funding
- Aventis Foundation
Ask authors/readers for more resources
A new FXR modulator chemotype has been discovered with tunable activity between agonism and antagonism through minor structural modifications, showing high selectivity and binding affinities. This new FXR ligand compound demonstrates good metabolic stability in cells and can serve as a novel scaffold for FXR-targeted drug discovery.
Therapeutic modulation of the bile acid-sensing transcription factor farnesoid X receptor (FXR) is an appealing strategy to counteract hepatic and metabolic diseases. Despite the availability of several highly potent FXR agonists structural diversity of FXR modulators is limited, and new ligand scaffolds are needed. Here we report structure-activity relationship elucidation of a new FXR modulator chemotype whose activity can be tuned between agonism and antagonism by two minor structural modifications. Starting from a weak FXR/PPAR agonist, we have developed selective FXR activators and antagonists with nanomolar to low-micromolar potencies and binding affinities. The new FXR ligand chemotype modulates the FXR activity in the native cellular setting, is endowed with favorable metabolic stability, and lacks cytotoxicity. It valuably expands the collection of FXR modulators as a new scaffold for FXR-targeted drug discovery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available